Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo

被引:149
作者
Xirodimas, D [1 ]
Saville, MK [1 ]
Edling, C [1 ]
Lane, DP [1 ]
Laín, S [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland
关键词
p53; p14ARF; Mdm2; ubiquitin; proteasome inhibition;
D O I
10.1038/sj.onc.1204656
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mdm2 has been shown to promote its own ubiquitination and the ubiquitination of the p53 tumour suppressor by virtue of its E3 ubiquitin ligase activity. This modification targets Mdm2 and p53 for degradation by the proteasome. The p14ARF tumour suppressor has been shown to inhibit degradation of p53 mediated by Mdm2. Several models have been proposed to explain this effect of p14ARF. Here we have compared the effects of p14ARF overexpression on the in vivo ubiquitination of p53 and Mdm2. We report that the inhibition of the Mdm2-mediated degradation of p53 by p14ARF is associated with a decrease in the proportion of ubiquitinated p53. The levels of polyubiquitinated p53 decreased preferentially compared to monoubiquitinated species. p14ARF overexpression increased the levels of Mdm2 but it did not reduce the overall levels of ubiquitinated Mdm2 in vivo. This is unexpected because p14ARF has been reported to inhibit the ubiquitination of Mdm2 in vitro. In addition we show that like p14ARF, the proteasome inhibitor MG132 can promote the accumulation of Mdm2 in the nucleolus and that this can occur in the absence of p14ARF expression. We also show that the mutation of the nucleolar localization signal of Mdm2 does not impair the overall ubiquitination of Mdm2 but is necessary for the effective polyubiquitination of p53. These studies reveal important differences in the regulation of the stability of p53 and of Mdm2.
引用
收藏
页码:4972 / 4983
页数:12
相关论文
共 37 条
[1]   Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation [J].
An, WG ;
Chuman, Y ;
Fojo, T ;
Blagosklonny, MV .
EXPERIMENTAL CELL RESEARCH, 1998, 244 (01) :54-60
[2]   Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo [J].
Bottger, A ;
Bottger, V ;
Sparks, A ;
Liu, WL ;
Howard, SF ;
Lane, DP .
CURRENT BIOLOGY, 1997, 7 (11) :860-869
[3]   An intact HDM2 RING-finger domain is required for nuclear exclusion of p53 [J].
Boyd, SD ;
Tsai, KY ;
Jacks, T .
NATURE CELL BIOLOGY, 2000, 2 (09) :563-568
[4]   MAPPING OF THE P53 AND MDM-2 INTERACTION DOMAINS [J].
CHEN, JD ;
MARECHAL, V ;
LEVINE, AJ .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (07) :4107-4114
[5]   The ubiquitin-proteasome pathway: on protein death and cell life [J].
Ciechanover, A .
EMBO JOURNAL, 1998, 17 (24) :7151-7160
[6]   Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53 [J].
Fang, SY ;
Jensen, JP ;
Ludwig, RL ;
Vousden, KH ;
Weissman, AM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) :8945-8951
[7]   The MDM2 RING-finger domain is required to promote p53 nuclear export [J].
Geyer, RK ;
Yu, ZK ;
Maki, CG .
NATURE CELL BIOLOGY, 2000, 2 (09) :569-573
[8]   Mdm2 promotes the rapid degradation of p53 [J].
Haupt, Y ;
Maya, R ;
Kazaz, A ;
Oren, M .
NATURE, 1997, 387 (6630) :296-299
[9]   Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 [J].
Honda, R ;
Tanaka, H ;
Yasuda, H .
FEBS LETTERS, 1997, 420 (01) :25-27
[10]   Activity of MDM2, a ubiquitin Ligase, toward p53 or itself is dependent on the RING finger domain of the ligase [J].
Honda, R ;
Yasuda, H .
ONCOGENE, 2000, 19 (11) :1473-1476